Quantcast

RIT and Stem Cell Transplant in AML

June 25, 2008

By Anonymous

THERAPY In an article e-publishedon April 16 ahead of print in the International Journal of Hematology, Koenecke et al. from the Hannover Medical School (Germany) reported on radioimmunotherapy (RIT) with ^sup 188^Re-labeled antiCD66 antibody in preconditioning for allogenic stem cell transplantation in high-risk acute myeloid leukemia (AML). The study included 21 patients (14 with high-risk AML; 6 with AML after myelodysplastic syndrome; and I with advanced myelodysplastic syndrome). All received the ^sup 188^Re-labeled anti- CD66 antibody in the conditioning regimen for allogeneic stem cell transplantation. Eleven patients proceeded to standard full-dose conditioning with busulfan and high-dose cyclophosphamide, and 10 patients proceeded to a reduced-intensity conditioning regimen. Patients received an unmanipulated allogeneic graft from alternative donors ( 15 patients) or a human leukocyte antigen-identical family donor (6 patients). Disease-free survival over a median follow-up of 42 mo was 43%. Treatment-related mortality was 28.6% (6 patients), and an additional 6 patients died of relapsing disease within 385 d of transplantation. At the time the article was submitted for publication, 9 patients were in complete hematologic remission. The authors concluded that in this challenging disease setting, “The combination of RIT with chemotherapeutic conditioning seems to be a therapy with an acceptable risk of treatment-related morbidity and mortality as well as occurrence of severe acute graft-versus-host disease.”

International Journal of Hematology Copyright Society of Nuclear Medicine Jun 2008

(c) 2008 Journal of Nuclear Medicine, The. Provided by ProQuest Information and Learning. All rights Reserved.




comments powered by Disqus